Veterinary Medicines Directorate

United Kingdom
Veterinary Medicines Directorate
Woodham Lane
New Haw
Addlestone
Surrey KT15 3LS

NATIONAL PROCEDURE

PUBLICLY AVAILABLE ASSESSMENT REPORT FOR A VETERINARY MEDICINAL PRODUCT

Alfadexx 2 mg/ml Solution for Injection for Horses, Cattle, Pigs, Dogs and Cats

Date Created: November 2021

MODULE 1

PRODUCT SUMMARY

Name, strength and pharmaceutical form	Alfadexx 2 mg/ml Solution for Injection for Horses, Cattle, Pigs, Dogs and Cats
Applicant	Alfasan Nederland B.V. Kuipersweg 9 3449 JA Woerden The Netherlands
Active substance	Dexamethasone 2 mg/ml
ATC Vetcode	QH02AB02
Target species	Horses, Cattle, Pigs, Dogs and Cats
Indication for use	<u>Horses, cattle, pigs, dogs and cats:</u> Treatment of inflammation and allergic reactions. <u>Horses:</u> Treatment of arthritis, bursitis or tenosynovitis. <u>Cattle:</u> Treatment of primary ketosis (Acetonemia). Induction of parturition.

MODULE 2

The Summary of Product Characteristics (SPC) for this product is available on the Product Information Database of the Veterinary Medicines Directorate.

(www.gov.uk/check-animal-medicine-licensed)

MODULE 3

PUBLIC ASSESSMENT REPORT

Legal basis of original application	Generic application in accordance with Article 13 (1) of Directive 2001/82/EC as amended.
Date of conclusion of the procedure	30th June 2021

I. SCIENTIFIC OVERVIEW

This was an application for a generic product, Alfadexx 20 mg/ml Solution for Injection for Horses, Cattle, Pigs, Dogs and Cats. The product has been developed as a generic of the product DEXADRESON, authorised in the UK since 1994. The product contains 2.0 mg/ml dexamethasone, (as dexamethasone sodium phosphate 0.63 mg/ml).

The product is indicated for use in hoses, cattle pigs, dogs and cats for the treatment of inflammation and allergic reactions. For the treatment of horses with arthritis, bursitis or tenosynovitis. For the treatment of cattle with primary ketosis (acetonemia), and induction of parturition.

The product is produced and controlled using validated methods and tests which ensure the consistency of the product released on the market. It has been shown that the product can be safely used in the target species, any reactions observed are indicated in the SPC.[1] The product is safe for the user, the consumer of foodstuffs from treated animals and for the environment, when used as recommended. Suitable warnings and precautions are indicated in the SPC. The efficacy [2] of the product was demonstrated according to the claims made in the SPC. The overall benefit/risk analysis is in favour of granting a marketing authorisation.

[1] SPC – Summary of product Characteristics.
[2] Efficacy – The production of a desired or intended result.

II. QUALITATIVE AND QUANTITATIVE PARTICULARS OF THE CONSTITUENTS

II.A. Composition

The product contains dexamethasone 2.0 mg/ml (as dexamethasone sodium phosphate 2.63 mg/ml), and the excipients benzyl alcohol (E1519), sodium chloride, sodium citrate, citric acid, sodium hydroxide and water for injections.

The container/closure system consists of 50 ml and 100 ml clear type I glass vials closed with a coated bromobutyl rubber stopper and aluminium cap in a carton box. The particulars of the containers and controls performed were provided and conform to the regulation.

The choice of the formulation and the presence of preservative are justified. The product is an established pharmaceutical form and its development is adequately described in accordance with the relevant European guidelines.

II.B. Description of the Manufacturing Method

The product is manufactured fully in accordance with the principles of good manufacturing practice from a licensed manufacturing site. The manufacturing method consists of the mixing of the ingredients and subsequent dissolution steps. Filtration, and pouring into vials.

Process validation data on the product have been presented in accordance with the relevant European guidelines.

II.C. Control of Starting Materials

The active substance is dexamethasone sodium phosphate, a novel active substance described in the European Pharmacopoeia (Ph. Eur). The active substance is manufactured in accordance with the principles of good manufacturing practice.

The active substance specification is considered adequate to control the quality of the material. Batch analytical data demonstrating compliance with this specification have been provided. An appropriate certificate of suitability was provided.

All excipients are described in the Ph. Eur, and suitable specifications were provided for the packaging materials.

II.C.4. Substances of Biological Origin

There are no substances within the scope of the TSE Guideline present or used in the manufacture of this product.

II.D. Control Tests Carried Out at Intermediate Stages of the Manufacturing Process

Not applicable.

II.E. Control Tests on the Finished Product

The finished product specification controls the relevant parameters for the pharmaceutical form. The tests in the specification, and their limits, have been justified and are considered appropriate to adequately control the quality of the product. Satisfactory validation data for the analytical methods have been provided. Batch analytical data from the proposed production site have been provided demonstrating compliance with the specification. Control tests on the finished product are those for: appearance, clarity, colour, pH, density, identification of active substance and related substances, volume and sterility.

II.F. Stability

Stability data on the active substance have been provided in accordance with applicable European guidelines, demonstrating the stability of the active substance when stored under the approved conditions.

G. Other Information

Shelf life of the veterinary medicinal product as packaged for sale: 3 years.
Shelf life after first opening the immediate packaging: 28 days.
Keep the vial in the outer carton in order to protect from light.

III. SAFETY AND RESIDUES DOCUMENTATION (PHARMACO-TOXICOLOGICAL)

As this is a generic application submitted according to Article 13 (1) of Directive 2001/82/EC as amended, and bioequivalence with a reference product has been justified, results of toxicological, pharmacological or clinical tests are not required.

III.A Safety Documentation

User Safety

A user risk assessment was provided in compliance with the relevant guideline.
Warnings and precautions as listed on the product literature are adequate to ensure safety to users of the product. Therefore the following applicant's user recommendations are appropriate:,

- This product contains dexamethasone which can cause allergic reactions in some people. People with known hypersensitivity to dexamethasone should avoid contact with the veterinary medicinal product.

- Care should be taken to avoid accidental self-injection. In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician.
- Dexamethasone may affect fertility or the unborn child. To avoid the risk from accidental self-injection, pregnant women should not handle this product.
- This product is a skin and eye irritant. Avoid contact with skin and eyes. In the event of accidental eye or skin contact, wash/irrigate the area with clean running water. Seek medical attention if irritation persists. Wash hands after use.

Environmental Safety

The Environmental Risk Assessment (ERA) was carried out in accordance with VICH and CVMP guidelines.

Phase I:

The product will only be used in non-food animals, (dogs and cats), or to treat a small number of animals herd, (horses, cattle and pigs), and as a result, environmental exposure will be low. A Phase II ERA was not required.

III.B.2 Residues documentation

MRLs

The active substance, dexamethasone, is included in table 1 of the annex of the Commission regulation (EU) No. 37/2010, as follows,

Marker residue	Animal Species	MRL	Target Tissues	Other Provisions	Therapeutic Classification	Regulation
Dexamethasone	Bovine, caprine, porcine, *Equidae*	0.75 µg/kg 2.00 µg/kg 0.75 µg/kg	Muscle Liver Kidney	No entry	Corticoids/ Glucocorticoids	37/2010 of 22.12.2009
	Bovine, caprine	0.30 µg/kg	Milk			

Residue Studies

No residue depletion studies were conducted due to the nature of the application.

Withdrawal Periods

Based on the data provided, withdrawal periods were established as follows:

Cattle:
Meat and offal: 8 days
Milk: 72 hours

Pigs:
Meat and offal: 2 days

Horses:
Meat and offal: 8 days
Not authorised for use in horses producing milk for human consumption.

IV. CLINICAL DOCUMENTATION

Tolerance in the Target Species

No tolerance studies were required based on the nature of the application.

Resistance

No resistance studies were required based on the nature of the application.
.

IV.II. Clinical Documentation

No clinical studies were required based on the nature of the application.

V OVERALL CONCLUSION AND BENEFIT– RISK ASSESSMENT

The data submitted in the dossier demonstrate that when the product is used in accordance with the Summary of Product Characteristics the benefit/risk profile of the product is favourable.

MODULE 4

POST- AUTHORISATION ASSESSMENTS

The SPC and package leaflet may be updated to include new information on the quality, safety and efficacy of the veterinary medicinal product. The current SPC is available on the Product Information Database of the Veterinary Medicines Directorate website.

(www.gov.uk/check-animal-medicine-licensed)

The post-authorisation assessment (PAA) contains information on significant changes which have been made after the original procedure which are important for the quality, safety or efficacy of the product.

The PAA for this product is available on the Product Information Database of the Veterinary Medicines Directorate website.

(www.gov.uk/check-animal-medicine-licensed)